氨基观察-创新药组原创出品作者 | 黄恺诺华天价药中国获批节点临近。7月14日,据CDE 官网,诺华基因治疗药物Zolgensma拟纳入优先审评,适用于治疗 6 月龄及以上5q型脊髓性肌萎缩症患者。Zolgensma的海外定价并不便宜,以每剂210万美元(约合人民币1495万元)的价格上榜全球十大最贵药物,位列第七。大冢制药收购自免新药。7月15日,大冢制药株式会社宣布,已与 Cantargia ...
Source Link氨基观察-创新药组原创出品作者 | 黄恺诺华天价药中国获批节点临近。7月14日,据CDE 官网,诺华基因治疗药物Zolgensma拟纳入优先审评,适用于治疗 6 月龄及以上5q型脊髓性肌萎缩症患者。Zolgensma的海外定价并不便宜,以每剂210万美元(约合人民币1495万元)的价格上榜全球十大最贵药物,位列第七。大冢制药收购自免新药。7月15日,大冢制药株式会社宣布,已与 Cantargia ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.